-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PIK3CA activating mutations can promote breast cancer resistance to HER2 targeted therapy
Breast cancer
This is a phase I study investigating the MTD of Alpelisib combined with trastuzumab and LJM716 (HER3 targeting antibody) for HER2-positive (HER2+) metastatic breast cancer (MBC) with PIK3CA mutation
Treatment remission of each group
Treatment remission of each groupTen patients in group A initially received Alpelisi treatment daily
Ten patients in group A initially received Alpelisi treatment daily
In group B, 11 patients received intermittent Alpelisib treatment with an MTD of 350 mg for 4 consecutive days, and then the drug was discontinued for 3 days
Of the 17 evaluable patients, 1 had a partial remission, 14 had a stable condition, and 2 had disease progression at the time of the best response
In summary, the combination therapy of Alpelisib, trastuzumab and LJM716 is limited by gastrointestinal toxicity
Original source:
Original source:Komal Jhaveri, et al.
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.
Leave a message here